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In myeloid malignancies, the neoplastic
clone outgrows normal hematopoietic
cells toward BM failure. This event is also
sustained by detrimental stromal changes,
such as BM fibrosis and osteosclerosis,
whose occurrence is harbinger of a dismal
prognosis. We show that the matricellular
protein SPARC contributes to the BM stro-
mal response to myeloproliferation. The
degree of SPARC expression in BM stro-
mal elements, including CD146 mesen-
chymal stromal cells, correlates with the
degree of stromal changes, and the sever-
ity of BM failure characterizing the proto-
typical myeloproliferative neoplasm pri-
mary myelofibrosis. Using Sparc/ mice
and BM chimeras, we demonstrate that
SPARC contributes to the development of
significant stromal fibrosis in a model of
thrombopoietin-induced myelofibrosis.
We found that SPARC deficiency in the
radioresistant BM stroma compartment
impairs myelofibrosis but, at the same
time, associates with an enhanced reac-
tive myeloproliferative response to throm-
bopoietin. The link betwen SPARC stro-
mal deficiency and enhanced myeloid cell
expansion under a myeloproliferative spur
is also supported by the myeloprolifera-
tive phenotype resulting from the trans-
plantation of defective Apcmin mutant he-
matopoietic cells into Sparc/ but not
WT recipient BM stroma. Our results high-
light a complex influence of SPARC over
the stromal and hematopoietic BM re-
sponse in myeloproliferative conditions.
(Blood. 2012;120(17):3541-3554)
Introduction
Bone marrow (BM) homeostasis stems from the regulated crosstalk
between hematopoietic and stromal components. Through this
interaction, hematopoietic stem cells (HSCs) are kept in a quiescent
state or driven toward differentiation. This crosstalk occurs within
specific stromal microenvironments termed “niches.”1 The osteo-
blastic/endosteal niche is composed of endosteal fibroblasts, osteo-
blasts, and bone-related extracellular matrix (ECM), the vascular
niche of endothelial cells and adventitial reticular cells. Signals
originating in these microenvironments orchestrate hematopoietic
cell localization, maturation, and mobilization dynamics respon-
sible for normal hematopoiesis,1 whereas a biased stromal niche
can lead to altered hematopoiesis, toward leukemogenesis.2
In myeloid malignancies, neoplastic clone expansion alters the
composition of the BM parenchyma and results in impaired
hematopoiesis and BM failure.3-5 In addition to direct replacement
of normal hematopoiesis, neoplastic proliferation generates detri-
mental alterations in the BM stroma.6-9 BM stromal changes
associated with myeloproliferation include excessive ECM deposi-
tion, which manifest as BM fibrosis,6-7 neoangiogenesis,8 and bone
abnormalities (osteosclerosis).6-7,9 These changes are variably
observed in acute myeloid leukemias (AMLs), myelodysplastic
syndromes (MDSs), and myeloproliferative neoplasms.6 In neo-
plasms characterized by a more gradual myeloproliferation, the
development of BM stroma alterations can represent the only sign
of disease progression.5,10
BM stromal alterations are of prognostic significance in my-
eloid malignancies. BM fibrosis is associated with a more aggres-
sive disease course and worse prognosis in patients with both
myeloproliferative neoplasm and MDS.6,11-15 In myeloproliferative
neoplasm, stromal changes may eventually cause the disruption of
normal HSC niches, which inhibits the growth of resident hemato-
poietic elements and results in the establishment of extramedullary
hematopoiesis.3-6,16 Moreover, stromal alterations may render the
HSC niche unfit for HSC seeding (supplemental Figure 1) and
negatively impact the outcome of allogeneic stem cell transplanta-
tion.17,18 Thus, BM stroma involvement in myeloid malignancies is
an integral part of the disease manifestations impacting the
outcome. However, little is known about the nature of stroma-
intrinsic factors and their role in BM stromal changes and myeloid
clone progression.
Secreted protein acidic and rich in cysteine (SPARC), also
known as osteonectin or BM-40, is a matricellular protein that
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plays a major role in the maintenance and restoration of tissue
homeostasis.19 SPARC has been implicated in tissue remodeling
during embryogenesis, wound healing, immune responses,20 cancer
stromatogenesis, and epithelial-to-mesenchymal transition.19-21
In myeloid malignancies, SPARC (5q31.3–32) deletion has been
associated with 5qMDS,22 and low or absent SPARC expression
has been reported in a subset of AML.23 Conversely, SPARC
overexpression characterizes CML cells displaying resistance to
imatinib in vitro, suggesting a role in myeloid clone progression.24
Herein, we investigated the role of SPARC in the BM stromal
alterations associated with myeloproliferation. Altogether, our
results suggest that stromal SPARC plays a key role in sustaining
the detrimental fibrosis that occurs in myeloid malignancies and
reveal SPARC’s influence on the BM hematopoietic response in
myeloproliferative conditions.
Methods
Patient samples
BM trephine biopsies (BMBs) of patients with myeloid malignancies were
selected from the archives of the Human Pathology Section, University of
Palermo. Ten consecutive AML cases, 10 MDS, 12 essential thrombo-
cytemia, 10 polycythemia vera (PV), and 56 primary myelofibrosis (PMF)
cases diagnosed between December 2008 and January 2011, according to
the 2008 WHO classification criteria,3 were included. Ten BMBs from
patients with reactive thrombocytosis and 6 BMBs of patients with Hodgkin
lymphoma without marrow involvement were used as controls. Only
representative BMBs8 collected at the time of diagnosis were included. For
all of the cases, the following presenting data were retrieved from the
patients’ medical records: age, sex, hemoglobin levels (Hb), peripheral
blood (PB) leukocyte count (white blood cell count), and platelet count
(PLT; Tables 1 and 2). All of the procedures were in accordance with the
Declaration of Helsinki.
Mice
BALB/cAnNCrl mice, 8-10 weeks old, were purchased from Charles River
Laboratories. The CNCr.129S(B6)–Sparctm1Hwe mice were developed
in our animal facility as previously described.25 Apcmin mice (B6, Ly5b)
were a kind gift of Dr Antonio Sica (Fondazione Istituto Clinico
Humanitas). Chimeric Sparc/  wild-type (WT; Thy-1b  Thy-1a),
WT  Sparc/(Thy-1a  Thy-1b), WT  WT(Thy-1a  Thy-1b),
Sparc/  Sparc/(Thy-1b  Thy-1b), Apcmin  WT (Ly5b  Ly5a),
and Apcmin  Sparc/ (Ly5b Ly5a) mice were obtained by BM transplan-
tation as previously reported.25 Engraftment was verified 6-8 weeks after
BM transplantation by FACS analysis of PB mononuclear cells accord-
ing to Thy-1a (BD Biosciences) and Thy-1b (BD Biosciences) or Ly5a
(BD Biosciences), and Ly5b (BD Biosciences) expression. The animal
experiments were authorized by the Institutional Ethical Committee for
Animal Use.
Table 1. Presenting clinical and laboratory features of myeloid neoplasm and control cases
AML MDS ET PV PMF Control
No. of cases 10 10 12 10 24 16
Mean age, y (range) 56.1 (31-77) 60.8 (36-80) 64.3 (30-80) 58.5 (34-85) 65.5 (40-86) 52.5 (21-85)
Sex, %
Male 27.2 50 83.3 30 58.3 43.7
Female 72.8 50 16.67 70 41.7 56.3
Cellularity, %* 80 (10-100) 68 (60-90) 43 (35-60) 83 (40-100) 75 (50-100) 48 (25-85)
Fibrosis grade† 1 2 1 1 1 0
Grade 0 0 0 33.3 0 8.4 50
Grade 1 70 40 66.6 60 45.8 50
Grade 2 20 50 0 20 20.8 0
Grade 3 10 10 0 20 25 0
WBC count, 109/L* 63.8 (1.6-420) 3.2 (1.2-5.2) 8.2 (4.1-13.2) 11.4 (4.9-22.6) 12 (2.3-51.5) 9.1 (2.2-14.6)
Hb, g/L* 83.6 (64-95) 88 (62-142) 130.6 (102-146) 160 (100-210) 122 (81-150) 128 (88-159)
PLT count, 109/L* 52.1 (16-146) 107.8 (19-264) 737.8 (411-942) 292.9 (126-494) 463.5 (13-1218) 305.9 (143-762)
*Values are mean (range).
†Fibrosis grade is reported as median (%) of each grade. Fibrosis is evaluated according to Thiele et al.7
Table 2. Presenting clinical and laboratory data of the 56 PMF cases
Prefibrotic/early fibrotic
(grade 0/1)*
Advanced fibrotic
(grade 2/3)* P†
Low/intermediate-1
risk‡
Intermediate-2/
high risk‡ P†
Sex, no. (%)
Male 9 (29) 14 (56) 14 (30.4) 9 (90)
Female 22 (71) 11 (44) 32 (69.6) 1 (10)
Age (y) at diagnosis* 63 (25-86) 65 (44-86) .86 62 (25-88) 71 (57-79) .1
Hb, g/L 131.6 (92-172) 111 (80-164) .0003 127.7 (87-172) 98 (80-127) .0004
WBC, 109/L 9.6 (3.8-15) 11.9 (2.8-51.5) .67 10.3 (3.8-22.1) 12.1 (2.8-51.5) .2
PLT, 109/L 662.7 (200-1218) 401 (49-1031) .004 605 (121-1218) 304 (490-753) .01
Cellularity, % 60.8 (20-90) 71.6 (30-100) .02 62.9 (20-100) 78 (50-90) .008
SPARC stromal cells  HPF 3.9 (0.5-15.9) 6.7 (2.4-15.7) .0003 4.7 (0.5-15.9) 7.3 (1.4-15.7) .004
CD146 stromal cells  HPF 6 (1-12.2) 10.2 (3.8-23.5) .0004 7.5 (1-23.5) 9.3 (3-21) .4
MVD  HPF 5.8 (1-12.2) 9.9 (2.8-18.6) .00001 6.5 (1.6-18.6) 8.5 (3-14.8) .1
Values are mean (range). HPF (400).
*Fibrosis was evaluated according to Thiele et al.7
†According to Mann-Whitney U test.
‡According to Cervantes et al.31
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In vivo recombinant TPO treatment
Recombinant murine thrombopoietin (TPO; PeproTech) or sterile saline
was injected intraperitoneally into WT, Sparc/, and chimeric mice once
daily (500 g/kg) for 10 or 14 consecutive days.26 After treatment, PB was
collected and analyzed for Hb, PLT, and circulating Gr1CD11b myeloid
cells. At the same time point, the mice were killed and their spleen, femurs,
and tibias were collected for histopathologic/immunophenotypical and
FACS analyses and for BM colony formation assays.
Histopathology and immunohistochemistry
Histopathologic analysis was performed on formalin-fixed, paraffin-
embedded specimens as previously reported.9,25 Four-micrometer-thick
sections were routinely stained with hematoxylin and eosin, Gomori
reticulin, and Masson trichrome stain.
The degree of BM fibrosis on human BMBs was semiquantitatively
assessed on Gomori-stained sections according to the European Consensus
Grading System,7 which ranges from 0 (normal BM fiber content) to
3 (diffuse and dense increase in reticulin with extensive intersections of
coarse collagen bundles, associated with osteosclerosis). A similar semiquan-
titative system was also adopted for BM fibrosis evaluation on Gomori-
stained mouse BM sections.
Immunohistochemistry was performed using the streptavidin-biotin-
peroxidase complex method as previously reported.9 The antibodies
adopted for immunohistochemistry are listed in supplemental Methods.
The slides were analyzed under a Leica-DM2000 optical microscope
(Leica Microsystems) using Leica 10 SL, HI PLAN 20/0.40, HI PLAN
40/0.65, HI PLAN 63/0.75, and PL FLUOTAR 100/1.30 objectives,
and microphotographs were collected using a Leica-DFC320 digital camera
and the Leica-IM50 Version 4.0 acquisition software (Leica Microsystems).
The number of SPARC and CD146 stromal cells was determined on
immunostained sections by counting the absolute number of reactive cells
with stromal morphology within 10 different high-power fields (HPFs;
400 magnification) and then averaging the counts obtained from the
10 fields. Similarly, microvascular density (MVD) was determined by
counting the number of CD34 vascular structures, as previously reported.9
Differential hematopoietic cell counts on mouse BM sections were
performed by counting the absolute number of neutrophils, eosinophils,
erythroid precursors, lymphoid cells, megakaryocytes (MKs), and
morphologically immature myeloid precursors of 10 HPFs, and then by
averaging the counts. The number of Ki-67 myeloid cells on BM
sections from mouse chimeras was similarly assessed of 10 HPFs, and
expressed as a mean.
Isolation, culture, and treatment of human and murine
BM-MSCs
Human BM mesenchymal stromal cells (BM-MSCs) were obtained from
aspirates of normal BM of patients undergoing hip replacement or Hodgkin
lymphoma staging. The samples were obtained with informed consent per
institutionally approved protocols, in accordance with the Declaration of
Helsinki. The BM-MSC cultures were established from plastic-adherent
BM cell fractions as detailed in supplemental Methods. Murine BM-MSCs
were obtained from the trabecular fraction of femurs and tibias of WT and
Sparc/ mice as previously reported,27 and cultures were established as
detailed in supplemental Methods.
In vitro experiments on human and murine BM-MSCs were performed
using cells between the second and fifth passages.
In vitro induction of human BM-MSCs toward osteoblastic or adi-
pocytic differentiation was performed by the use of specific culturing media
(StemCell Technologies) as detailed in supplemental Methods.
Stimulation with recombinant TGF-1 (rTGF-1) was performed on
murine BM-MSCs obtained from WT and Sparc/ mice. The cells were
seeded into 6-well plates in complete medium at 70%-80% of confluence,
starved for 24 hours in serum-free medium (Invitrogen), and treated with
rTGF-1 10 ng/mL (R&D Systems) for 48 hours before Western blot (WB)
analysis.
For WB analysis, human and murine BM-MSC whole cell lysates were
resolved by SDS-PAGE and transferred to nitrocellulose membranes (GE
Healthcare).25 The antibodies used are detailed in supplemental Methods.
Densitometric analysis was performed using the ImageQuant TL Version 7
software (GE Healthcare Life Sciences).
Coculture experiments between WT or Sparc/ murine BM-MSCs and
WT lineage negative (Lin) hematopoietic cells have been performed
according to Walenda et al,28 as detailed in supplemental Methods.
Immunofluorescence and confocal microscopy
For in vitro immunofluorescence analysis, human and murine BM-MSCs
were seeded into Fluorodish tissue culture dishes (World Precision Instru-
ments), fixed in the plate with 2% PFA, and treated with 0.1% Triton
X-100/PBS before incubation with the antibodies. The stained cells were
analyzed under a RADiance-2000 (Bio-Rad) Nikon-TE300 laser scanning
confocal microscope (Nikon).
For double-marker immunofluorescence on BM tissue, sections under-
went 2 sequential rounds of single-marker immunostaining as previously
reported.9 The slides were evaluated under a Leica-TCS-SP5 laser scanning
confocal microscope (Leica Microsystems) using HC PL APO 20/0.70 and
HCX PL APO CS 40/1.25-0.75 objectives.
All of the antibodies used for immunofluorescence are detailed in
supplemental Methods.
FACS analysis
FACS analysis was performed to assess the phenotype of human and mouse
BM-MSCs, to determine the host or donor origin of the BM stromal cells in
BM chimeras, and to evaluate the fractions of murine BM precursor
populations (Linc-kit, CMP, GMP, MEP) and circulating Gr1CD11b
myeloid cells. The antibodies used are detailed in supplemental Methods.
Data were acquired using a BD Fortessa cytofluorimeter (BD Biosciences)
and analyzed with FlowJo Version 8.8.6 analysis software (TreeStar).
BM colony formation assay
BM cells were obtained by flushing the femurs and tibias. The cells were
then plated and cultured in MethoCult-GF-M3434 complete methylcellu-
lose medium (StemCell Technologies), as previously described.29 After
10 days, colonies were scored for colony-forming unit-granulocyte,
-erythrocyte, -monocyte, -MK (CFU-GEMM), granulocyte-macrophage
colony-forming unit (CFU-GM), and burst-forming unit-erythroid (BFU-
E). Photomicrographs were collected following 2% PFA fixation under a
Nikon-TM2000 microscope (Nikon) equipped with a Nikon-DXM1200
digital camera (Nikon).
GEP analysis
Whole transcriptome analysis was performed on data previously generated
from different subsets of human BM mesenchymal and hematopoietic cells
that was available at the NCBI Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/). For details, see supplemental Methods
and supplemental Table 1.
GEP analysis was performed using GeneSpring Software (Agilent
Technologies), as previously reported.30 The EASE Version 2.0 software
(National Institute of Allergy and Infectious Diseases, National Institutes of
Health) was applied to establish whether specific cell functions and biologic
processes, defined according to gene ontology, were significantly repre-
sented among the deregulated genes.30
Statistical analysis
Continuous and categorical variables were compared using the Mann-
Whitney U test.
Correlation between variables was assessed using Pearson and Spear-
man coefficients. Analysis of the effects of TPO treatment and Sparc
genotype on BM hematopoiesis was performed by 2-way ANOVA. Data
were analyzed with the Statistical Package for the Social Sciences Version
13.0 (IBM) software.
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Results
SPARC stromal expression characterizes myeloid
malignancies with BM stroma alterations and correlates with
signs of BM failure
Because of the pleiotropic role of SPARC in tissue remodeling, we
investigated whether its expression had any role in the stromal
alterations associated with myeloid malignancies. Initially, we
immunohistochemically tested SPARC expression in BMBs from
66 patients with different types of myeloid neoplasms and variable
degrees of associated stromal changes, namely, BM fibrosis and/or
osteosclerosis, and in 16 control BMBs. The clinical characteristics
of these patients are summarized in Table 1.
In control cases and in myeloid neoplasms without associated
stromal changes, such as essential thrombocytemia, early PV, and
prefibrotic PMF, SPARC expression was confined to MKs (Figure
1A black arrows; supplemental Figure 2A). By contrast, in cases
with significant stromal alterations, such as overt PMF, MDS with
fibrosis (MDS-F), and acute panmyelosis with myelofibrosis,
SPARC expression was also identified in spindle to stellate BM
stromal cells intermingling with hematopoietic cells, branching
around vessels or forming an intricate meshwork (Figure 1A green
arrows; supplemental Figure 2A).
We subsequently investigated whether stromal SPARC expres-
sion correlated with histopathologic and laboratory variables of
clinical significance in myelofibrotic myeloid neoplasms5 using
PMF as a prototypical model. The number of SPARC-expressing
Figure 1. SPARC stromal expression and features of
BM failure are correlated in myelofibrotic myeloid
malignancies. (A) Immunohistochemical analysis of
SPARC expression (aminoethyl-carbazole [AEC], red
signal) on BM sections from control (Reactive BM) and
myeloid neoplasm (MDS-F; PMF-3) cases. In normal BM
that is free of stromal alterations, SPARC expression is
confined to MKs (left panel, black arrows, inset). How-
ever, in marrow with myeloproliferation-associated stro-
mal alterations, SPARC reactivity extends to stromal cells
with spindle to stellate morphology (central and right
panels, green arrows, insets). Three representative cases
of the 114 cases evaluated are shown. Original magnifica-
tions 200, insets 630. Scale bars represent 100 m.
(B) The number of SPARC stromal cells, assessed in
56 PMF cases, is significantly correlated with relevant
biologic, clinical, and prognostic features: BM fibrosis;
prognostic risk group according to Cervantes et al.31
MVD; CD146 mesenchymal stromal cells. *P  .05.
Box plot and scattergrams have been plotted to allow
distinction between early (prefibrotic/grade 1 fibrosis)
and advanced PMF cases (grade 2 or 3 fibrosis).
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stromal cells was assessed in 56 consecutive cases of PMF and
correlated with the following variables: BM cellularity, degree of
BM fibrosis, MVD, age, sex, Hb, complete PB counts, and PMF
prognostic score according to Cervantes et al.31 In addition, a
correlation was made with the number of CD146-expressing
BM-MSCs,1,32 which we have reported to increase proportionally
with the degree of stromal changes that occur along PMF progres-
sion (supplemental Figure 3).9 The clinical and laboratory features
of these PMF cases are summarized in Table 2.
We found that the number of SPARC stromal cells correlated
significantly with the degree of BM fibrosis (rho 0.583, P .01),
MVD (rho  0.550, P  .0001), and the number of CD146
BM-MSCs (rho  0.632, P  .00001), reflecting the entity of
stromal disarrangement (Table 2; Figure 1B). Moreover, the
number of SPARC stromal cells was higher in PMF patients
belonging to a higher prognostic risk group (low/intermediate-1 vs
intermediate-2/high, P  .04), and correlated with signs of BM
hematopoietic failure, such as low Hb levels (rho  0.429 vs Hb
level, P  .002) and thrombocytopenia (rho  0.539 vs PLT
count, P  .00001; Table 2; Figure 1B). The significant difference
in the mean number of SPARC stromal cells per HPF among cases
with different degrees of BM fibrosis was also confirmed in PV,
MDS, and AML (supplemental Figure 2B).
These data indicate a correlation between SPARC stromal
expression and the establishment of relevant BM fibrotic changes that
parallel the progressive failure of normal BM hematopoiesis in PMF.
SPARC expression marks CD146 BM-MSCs and is associated
with the osteoblastic milieu expansion underlying
osteosclerotic progression
CD146 BM-MSCs are the mesenchymal precursors of BM
stromal cells, including fibroblasts, BM reticular cells, adipocytes,
and osteoblasts. In human BM, BM-MSCs display a spindle to
stellate branching morphology and subendothelial distribution.1,9,32
The concurrent changes in SPARC cells and CD146-expressing
BM-MSCs in PMF cases, and the morphology and distribution of
several SPARC stromal cells mirroring those of CD146 cells
(Figure 2A black arrows), prompted us to test whether CD146
BM-MSCs were a source of SPARC in myeloid neoplasms with
stromal alterations. Double immunofluorescence analysis for
SPARC and CD146 in 30 cases of myeloid neoplasms with variable
degrees of stromal fibrosis (range, 0-3, including 18 cases of PMF,
8 cases of PV, and 4 cases of MDS) showed that, aside from MKs
and some stromal cells that were marked by SPARC but not CD146
(Figure 2B white arrows), SPARC expression overlapped that of
CD146 in BM-MSCs displaying subendothelial localization (Fig-
ure 2B yellow arrows).
The BM stromal alterations associated with myelofibrotic
myeloid malignancies may progress toward osteosclerosis (supple-
mental Figure 4), which could reflect an imbalance in the differen-
tiative fate of BM-MSCs at the bifurcation between the osteoblastic
and adipocytic differentiation, a checkpoint in which SPARC is
involved (supplemental Figure 5).33,34 We thus focused on the
expression of SPARC and key ECM components of the osteoblastic
niche, namely, collagen type I and fibronectin, in advanced PMF
cases undergoing osteosclerotic progression. Expression of colla-
gen type I and fibronectin, which was confined to the endosteal
edge of the hematopoietic parenchyma in PMF cases without
relevant stromal alterations (Figure 2C arrows), spread to the
intertrabecular areas in cases with severe fibrosis and osteosclerosis
(Figure 2C). Interestingly, in these cases, SPARC colocalized with
collagen type I in sclerotic foci in situ (Figure 2D), as assessed by
double immunofluorescence, and exhibited strong expression in osteo-
blasts at sites of osteosclerotic bone formation (Figure 2E arrows).
The in situ association between SPARC and foci of new bone
formation was in line with the whole transcriptome GEP analysis
that we performed on a panel of human samples representative of
BM hematopoietic and mesenchymal cells (supplemental Table 1),
including samples of BM-MSCs committed to osteoblastic differen-
tiation. The list of SPARC best correlates (204 unique genes with
Pearson correlation r2  0.95; supplemental Table 2) was signifi-
cantly enriched in key genes involved in cell adhesion/motility and
communication (eg, TGFB1 and PDGFRA), and ECM composition
(supplemental Tables 2 and 3). Notably, among these, we found
ECM genes involved as critical regulators of the osteoblastic
milieu, such as COL1A2, COL3A1, COL5A1/A2, COL12A1, and
FN (supplemental Figure 6).35-37
Altogether, these results associate SPARC with advanced
osteosclerotic modifications, which may develop in myeloprolifera-
tive malignancies as a result of skewed BM-MSC differentiation
dynamics.
Stromal SPARC is required for BM fibrotic changes
accompanying TPO-induced reactive myeloproliferation
To investigate the relevance of SPARC in the induction of BM
fibrotic changes associated with myeloproliferation, we adopted a
murine experimental model of myelofibrosis. In mice, reactive
myeloproliferation and associated stromal fibrosis could be in-
duced by recombinant TPO treatment, as previously reported.26
Thus, WT and Sparc/ mice were treated intraperitoneally with
TPO at a daily dose of 500 g/kg for 10 or 14 days, killed, and
analyzed for signs of myeloproliferation, and associated BM
stroma alterations.
WT and Sparc/ mice both developed myeloproliferation in
the BM after 10 days of TPO treatment (Figure 3A). Myeloprolif-
eration was paralleled by extramedullary splenic hematopoiesis
with red pulp expansion (Figure 3B), PB thrombocytosis, and
anemia (supplemental Figure 7A). BM histopathology and differen-
tial hematopoietic cell counts on BM sections highlighted that,
differently from saline-treated controls, TPO-treated mice were
characterized by increased BM cellularity with expansion of
granulocytes and immature myeloid cells, and by MK hyperplasia
with marked pleomorphism and cluster formation (Table 3; Figure
3A,C). Comparable results were obtained by 14 days TPO treat-
ment (not shown).
In TPO-treated WT mice, myeloproliferation was associated
with the development of moderate to severe stromal fibrosis and
osteosclerotic foci (Figure 3A inset). Interestingly, none of the
TPO-treated Sparc/ mice displayed severe fibrosis or signs of
osteosclerosis (Figure 3A). According to the histopathologic grad-
ing of BM fibrosis, which ranged from 0 to 3, the mean score of WT
TPO-treated mice was 2.2 (SD, 0.76) compared with 0.8 of
Sparc/ mice (SD, 0.84; P  .013), whereas control marrows
from both WT and Sparc/ saline-treated mice scored 0 (Figure
3D). These in vivo results demonstrate that the absence of SPARC
hampers the development of stromal fibrosis associated with
TPO-induced reactive myeloproliferation.
To determine the cellular source of SPARC, either hematopoi-
etic or stromal, relevant to the formation of BM stromal fibrosis,
BM chimeras were generated in which WT or Sparc/ mice were
either donors or hosts, as well as Thy-1 (CD90) congenic. Because
of the low Thy-1 expression in murine BM-MSCs, to verify whether
BM stromal cells were substituted or not by BM transplantation,
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(CxB6)F1 mice expressing H-2Kb-d MHC class I were transplanted
with marrows from B6 mice expressing H-2Kb to follow MHC
class I genotype in BM-MSCs. Flow cytometric analysis revealed
that almost all of the nonhematopoietic CD44 and CD146 cells
(gated on the CD45.2 population) expressed the host H-2Kd MHC
class I molecule (supplemental Figure 8A), thus confirming that
BM mesenchymal cells remained of host origin after transplantation.
Six weeks after BM transplantation, WTWT, Sparc/WT,
WT  Sparc/, and Sparc/  Sparc/ chimeras were evalu-
ated for reconstitution with donor hematopoietic cells and treated
with high-dose TPO as detailed in “Methods.” In all of the
chimeras, TPO treatment induced significant myeloproliferation in
the BM and spleen (Figure 4A-B; Table 4), thrombocytosis, and
anemia (supplemental Figure 7B). The Sparc genotype of the
radioresistant stroma was determinant for the development of
myeloproliferation-related stromal changes. Indeed, although TPO-
treated BM chimeras with host WT stroma showed marked
fibrosis associated with myeloproliferation (Figure 4A, arrows),
those with Sparc/ recipient stroma developed slight or no
fibrosis, regardless of the genotype of the BM donor. Specifi-
cally, the mean histopathologic scores of BM fibrosis for TPO-treated
WT  WT and Sparc/  WT chimeras were 2.6 (SD, 0.55) and
2.8 (SD, 0.45), respectively, compared with 0.8 (SD, 0.55) of
WT Sparc/ and 0.6 (SD, 0.89) of Sparc/ Sparc/ chimeras
(WTWT vs WT Sparc/, P .004; Sparc/ WT vs
Sparc/ Sparc/, P  .001; Figure 4C). The phenotype of such
chimeras was consistent with the in situ SPARC expression
detected by immunohistochemistry (supplemental Figure 8B).
These results confirm that SPARC contributes to the induc-
tion of BM stromal changes driven by myeloproliferation and
identify BM stromal cells as the relevant source of SPARC in
this setting.
Figure 2. SPARC is expressed by CD146 BM-MSCs and associates with components of the expanded osteoblastic niche in osteosclerosis. (A) Immunohistochemi-
cal analysis of SPARC and CD146 (AEC, red signal) expression in PMF BM sections. Several SPARC-expressing stromal cells show subendothelial distribution and reticular
morphology (black arrows, inset), which overlap those of CD146 BM-MSCs (black arrows, inset). Representative immunostained sections of the 114 evaluated are shown.
Original magnifications 400, insets 630. Scale bars represent 50 m. (B) Confocal microscopic analysis for SPARC (green signal) and CD146 (red signal) expression in
PMF shows that, in addition to MKs and stromal cells expressing SPARC (white arrows), a subset of stromal cells with a perivascular distribution coexpresses SPARC and
CD146 (yellow arrows and insets). Representative immunostained section of the 30 evaluated is shown. Original magnifications 200 (top panels) and 400 (bottom panels
and insets). Scale bars represent 100 and 50 m, respectively. (C) Immunohistochemical analysis for collagen type I (Coll-I) and fibronectin (Fibro; 3-3	-diaminobenzidine
[DAB], brown signal) in sections from prefibrotic (PMF-0) and advanced PMF (PMF-3) cases. In the former (left panels), the 2 ECM components display selective localization at
the endosteal edge of the bone trabeculae (black arrows) while undergoing a significant increase in expression and diffusion in the latter (right panels). Representative
immunostained sections of the 30 evaluated are shown. Original magnifications 400. Scale bars represent 50 m. (D) Confocal microscopic analysis for SPARC (red signal)
and collagen type I (Coll-I, green signal) expression showing that these 2 proteins colocalize in the sclerotic foci of an advanced PMF case (PMF-3). Representative
immunostained sections of the 30 evaluated are shown. Original magnifications 200. Scale bars represent 100 m. (E) Immunohistochemical analysis of SPARC (red signal)
showing its expression in osteoblasts (black arrows) lining bone trabeculae in myeloid malignancies undergoing osteosclerotic progression (PMF-3). Representative
immunostained sections from 2 cases of the 30 evaluated are shown. Original magnifications 400 (left panel) and 630 (right panel). Scale bars represent 50 and 30 m,
respectively.
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Because chimeras with a Sparc/ stroma failed to develop
significant stromal alterations, we tested whether WT and Sparc/
BM-MSCs respond differently to the prototypical epithelial-to-
mesenchymal transition inducer TGF-1 in vitro. BM-MSCs from
WT and Sparc/ mice, whose phenotype is reported in supplemen-
tal Figure 9, were starved for 24 hours in serum-free medium
before the addition of rTGF-1. After 48 hours, confocal micros-
copy analysis of SPARC expression and collagen type I deposition
revealed that rTGF-1 treatment induced up-regulation of SPARC
and concurrent collagen type I fiber deposition in WT BM-MSCs
(Figure 5A top panels), whereas Sparc/ MSCs were refractory to
TGF-1-induced collagen deposition (Figure 5A bottom panels),
Figure 3. The development of TPO-induced experimental BM fibrosis in mice requires SPARC. WT and Sparc/ mice were treated with recombinant TPO to induce
myeloproliferation and fibrosis (n  5 mice per condition, per experiment). Control mice were treated with the medium alone (sterile saline with 1% normal mouse serum). The
data represent 1 experiment of the 3 performed. (A) Hematoxylin and eosin and Gomori staining of BM samples from TPO-treated WT and Sparc/ mice. Hematoxylin and
eosin staining shows that TPO administration induced granulocytic and megakaryocytic hyperplasia with MK atypia and cluster formation in both strains (hematoxylin and eosin
panels, black arrows), which was not observed in sections from saline-treated mice. A significant degree of stromal fibrosis was observed in WT mice treated with TPO, which is
highlighted by the presence of a network of black-stained fibers (Gomori panels, black arrow) and foci of osteosclerosis (Masson trichrome stain, inset). However, BM sections
of TPO-treated Sparc/ mice were completely free of signs of fibrosis similarly to the saline-treated WT and Sparc/ mice (Gomori panels). Original magnifications 400.
Scale bars represent 50 m. (B) Histopathologic analysis of the spleen architecture of control and TPO-treated WT and Sparc/ mice showing that the splenic parenchyma of
treated mice is characterized by effacement of the white pulp (WP) because of the expansion of the red pulp (RP) with prominent megakaryocytic hyperplasia and clustering
(insets). Original magnifications 100, insets 200. Scale bars represent 200 m. (C) Differential hematopoietic cell counts (mean 
 SD) performed on BM sections of WT
and Sparc/ control and treated mice showing the significant increase in BM hematopoietic cells after TPO treatment. In each BM sample, the number of neutrophils,
eosinophils, morphologically immature myeloid cells, erythroid cells, MKs, and lymphoid cells was counted of 10 HPFs. *P  .05. (D) Histopathologic grading of BM fibrosis in
saline- and TPO-treated WT and Sparc/ mice performed on Gomori-stained BM sections according to a 4-grade semiquantitative scoring system (see “Methods”). The mean
grade of fibrosis is significantly higher in TPO-treated WT mice than in TPO-treated Sparc/ mice. *P  .05.
Table 3. Differential hematopoietic cell counts on BM sections in control and TPO-treated WT and Sparc/ mice
WT saline Sparc/ saline WT TPO Sparc/ TPO
P value
of treatment
P value of host
SPARC genotype
Neutrophils 81 
 12.3 92.8 
 11.9 143.4 
 19.9 163.8 
 7.0  .0001 .0208
Eosinophils 6.6 
 2.1 13.4 
 3.5 8.4 
 2.9 7.6 
 2.5 .9315 .3508
Immature myeloid cells 26.2 
 6.3 35.8 
 9.1 52 
 7.6 68 
 9.1  .0001 .0208
Erythroid cells 69 
 15.7 68.4 
 13.6 65 
 8.3 41.8 
 6.9 .0101 .0375
Megakaryocytes 10.2 
 2.8 13.4 
 2.2 54.4 
 8.9 65.8 
 8.7 .0001 .0226
Lymphoid cells 29.8 
 7.9 40.6 
 12.2 50.8 
 9.1 60.8 
 7.1 .0001 .075
Data have been analyzed with a 2-way ANOVA. P value expresses how the treatment (TPO) and the Sparc host genotype affect the variables.
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supporting that BM-MSCs intrinsically require SPARC for a proper
fibrotic response. WB analysis confirmed the induction of SPARC
up-regulation by TGF-1 in WT BM-MSCs and showed that WT
and Sparc/ BM-MSCs differed in the cellular content of the
mature collagen form (Figure 5B-C), which was only detectable in
WT cells. Notably, TGF-1, whose expression in WT cells
paralleled SPARC modulation, was basally more expressed in
Sparc/ BM-MSCs and was slightly up-regulated after exogenous
rTGF-1 stimulation (Figure 5B), suggesting that defective colla-
gen type I maturation and deposition occurring in the absence of
SPARC were not the result of impaired TGF-1 synthesis.
Therefore, the defective collagen matrix deposition characteriz-
ing Sparc/ BM-MSCs is responsible for the reduced fibrosis of
TPO-treated Sparc/ recipient chimeras, as also supported by
Figure 4. BM stromal cells are the relevant source of SPARC in the development of experimental BM fibrosis. BM chimeras were obtained by transplanting WT and
Sparc/ mice with either WT or Sparc/ BM cells to obtain WT  WT, Sparc/  WT, WT  Sparc/, and Sparc/  Sparc/ BM chimeras. Chimeras were treated with
either recombinant TPO to induce myeloproliferation and fibrosis or medium alone as a control (n  5 mice per group, per experiment). The data shown represent 1 experiment
of the 3 performed. (A) Histopathologic analysis of BM samples from TPO-treated BM chimeras. Hematoxylin and eosin staining shows signs of myeloproliferation in all of the
different types of BM chimeras, which include marked granulocytic and megakaryocytic hyperplasia with MK clustering (hematoxylin and eosin panels). A considerable degree
of dysgranulopoiesis and megakaryocytic atypia is observed in chimeras with a Sparc/ recipient (WT  Sparc/, Sparc/  Sparc/). Gomori staining shows a significant
degree of stromal fibrosis only in BM chimeras in which the recipient is WT (WT  WT, Sparc/  WT), as highlighted by the presence of an intricate network of black-stained
fibers (Gomori panels, black arrows). By contrast, no stromal fibrosis is detected in TPO-treated chimeras in which the recipient is Sparc/, irrespective of Sparc genotype of
the donor. Original magnifications 400. Scale bars represent 50 m. (B) Histopathologic analysis of the splenic architecture of control and TPO-treated chimeric mice
showing that the splenic parenchyma of treated mice is characterized by effacement of the white pulp (WP) because of the expansion of the red pulp (RP) with prominent
megakaryocytic hyperplasia and clustering (insets). Original magnifications 100, insets 200. Scale bars represent 200 m. (C) Grading of BM fibrosis in TPO-treated BM
chimeric mice was performed on Gomori-stained BM sections according to a 4-grade semiquantitative scoring system (see “Histopathology and immunohistochemistry”). The
mean grade of fibrosis is significantly higher in TPO-treated chimeric mice with a WT recipient than in those with Sparc/ recipients. **P  .01.
Table 4. Differential hematopoietic cell counts on BM sections in control and TPO-treated chimeric mice
WT > WT
saline
WT > Sparc/
saline
Sparc/ >
WT saline
Sparc/ >
Sparc/
saline
WT > WT
TPO
WT > Sparc/
TPO
Sparc/ >
WT TPO
Sparc/ >
Sparc/ TPO
P value of
treatment
P value of
host SPARC
genotype
Neutrophils 89.6 
 7.63 113.8 
 13.0 114.0 
 8.3 122.2 
 5.4 138.7 
 15.3 164.33 
 19.3 156.2 
 19.9 182 
 8.13  .0001  .0001
Eosinophils 4.2 
 1.8 3.0 
 1.2 3.4 
 1.1 4 
 1.2 12.1 
 3.2 10.5 
 1.4 13.1 
 2.9 12.3 
 2.0  .0001 .2443
Immature myeloid
cells
31.6 
 7.2 37.6 
 9.8 41 
 7.1 46.2 
 4.1 46.3 
 4.7 56.2 
 5.5 44.3 
 5.4 61.3 
 6.6  .0001 .0004
Erythroid cells 66.8 
 10.3 69.2 
 7.2 69.2 
 5.11 68.8 
 6.1 52.7 
 9.5 40 
 4.9 38.7 
 7.5 33.5 
 10.1  .0001 .1241
Megakaryocytes 11.6 
 3.6 11.6 
 3.2 12.8 
 2.4 14 
 1.6 49 
 2.3 62.3 
 3.4 53 
 13.0 74.8 
 5.6  .0001  .0001
Lymphoid cells 44.6 
 10.2 52.0 
 13.8 54.6 
 10.3 54.8 
 8.7 46.8 
 5.0 54.5 
 4.9 34.5 
 7.4 28 
 7.6 .0011 .0405
Data have been analyzed with a 2-way ANOVA. P value expresses how the treatment (TPO) and the Sparc host genotype affect the variables.
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in situ defective expression of collagen type I in the presence of
conspicuous TGF-1 expression (Figure 5D-E). TGF-1 was more
expressed in the stroma of Sparc/ recipient chimeras, than in WT
counterparts (Figure 5E, arrows), which was consistent with the
in vitro WB analysis of TGF-1 expression on WT and Sparc/
BM-MSCs.
SPARC deficiency in the BM stroma associates with an
enhanced myelopoietic response to TPO
The analysis of BM chimeras, although crucial for dissecting the
role of hematopoietic cell-derived and stroma-derived SPARC in
BM fibrosis, uncovered that stroma-derived SPARC may affect
myelopoiesis under a myeloproliferative stress, such as TPO
treatment.
Indeed, TPO-induced reactive myeloproliferation in chimeras
with a Sparc/ stroma was characterized by increased granulopoi-
esis with enrichment of immature myeloid precursors, and by a
higher degree of megakaryocytic hyperplasia with dysmegakaryo-
poiesis (ie, micromegakaryocytes with small hypolobulated nuclei)
compared with chimeras with a WT stroma (Table 4; Figure 6A-B).
Accordingly, a significant increase in myeloid colony forming units
(CFU-GM; Figure 6C-D; WT  Sparc/ vs WTWT, P .038;
Sparc/  Sparc/ vs Sparc/  WT, P  .020) and an in-
crease in the fraction of GMP BM hematopoietic precursors
Figure 5. BM-MSCs from Sparc/ mice are defective in collagen type I deposition despite high TGF-1 synthesis. (A) In vitro confocal microscopic analysis for
collagen type I (green) and SPARC (red) expression in BM-MSCs obtained from WT and Sparc/ mice. BM-MSCs were seeded onto culture dishes adapted for confocal
microscopy, starved for 24 hours, and then treated with recombinant TGF-1. Untreated cells served as the control. The images show that rTGF-1 administration induced
SPARC up-regulation and collagen type I fiber deposition only in WT BM-MSCs. Results of 1 representative experiment of the 3 performed in triplicate are shown. Original
magnifications 400. Scale bars represent 50 m. (B) Western blot analysis for collagen type I, SPARC, and TGF-1 on whole cell lysates from BM-MSCs treated rTGF-1.
Untreated cells served as the control. Western blot analysis highlights a different pattern of collagen type I production by WT and Sparc/ BM-MSCs. Specifically, WT
BM-MSCs produce both the mature form of collagen (79 kDa) and precursors of low molecular weight (predicted molecular weight of 107-120 kDa). In contrast, Sparc/
BM-MSCs were unable to produce the mature form of collagen (79 kDa) and accumulated precursors of high molecular weight (223 kDa), which indicates a defect in collagen
maturation in Sparc/, but not WT, BM-MSCs. WB analysis also showed that WT BM-MSCs up-regulate SPARC expression after rTGF-1 administration. The results of
1 representative experiments of the 3 performed in triplicate are shown. (C) Western blot quantitative analysis of SPARC expression performed on WT BM-MSCs treated with
rTGF-1. Untreated cells served as the control. The data represent 1 experiment of the 3 performed in triplicate. (D) Immunohistochemical analysis of collagen type I
expression (DAB, brown signal) in BM samples from mouse chimeras showing that chimeric mice with WT stroma (WT  WT, Sparc/  WT) have significantly higher
interstitial deposition of collagen type I (left panels, black arrows) compared with chimeras with Sparc/ BM stroma (WT  Sparc/, Sparc/  Sparc/; right panels). Four
representative immunostained sections (1 per group) are shown of the 20 evaluated. Original magnifications 400. Scale bars represent 50 m. (E) Immunohistochemical
analysis of TGF-1 expression (DAB, brown signal) in BM samples from TPO-treated mouse chimeras showing that a higher density of BM stromal cells expressing TGF-1
(arrows) is detected in chimeras with a Sparc/ BM stroma (WT  Sparc/, Sparc/  Sparc/; right panels) compared with the WT counterpart (WT  WT,
Sparc/  WT; left panels). Four representative immunostained sections (1 per group) are shown of the 20 evaluated. Original magnifications 400. Scale bars
represent 50 m.
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(WT  Sparc/ vs WT  WT, P  .028; Sparc/  Sparc/
vs Sparc/  WT, P  .029; Figure 6E) were observed in TPO-
treated chimeras with a Sparc/ host genotype compared with the
WT counterparts, suggesting that the expansion of selected myeloid
progenitor cell populations was favored by SPARC stromal deficiency.
Moreover, the number of Ki-67 BM myeloid cells was significantly
higher in WT Sparc/ (mean
 SD: 9.6
 1.50 cells/HPF) and
Sparc/ Sparc/ (10.1
 1.85 cells/HPF) chimeras compared with
WTWT (4.3
 1.16 cells/HPF) and Sparc/WT counterparts
(4.1 
 0.99 cells/HPF; WT  Sparc/ vs WT  WT P  .001;
Sparc/  Sparc/ vs Sparc/  WT P  .001; supplemental
Figure 10A). Flow cytometric analysis on PB revealed a significant
increase in the fraction of circulating Gr1CD11b myeloid cells
in chimeras with Sparc/ stroma compared with those with WT
stroma (Figure 6F). In the PB smears of TPO-treated Sparc/
recipients, a higher frequency of bandform stage immature granulo-
cytes and pseudo-Pelger-Hu¨et figures (Figure 6G) were detected,
further supporting the enhanced myelopoietic response to TPO in
the absence of stromal SPARC.
The different support of Sparc/ BM mesenchymal cells to
myelopoiesis also emerged by in vitro coculture experiments in
which Lin hematopoietic cells from WT mice were cocultured
with either WT or Sparc/ BM-MSCs in the presence of stem cell
factor and TPO. After 7 days of coculture, hematopoietic cells were
analyzed by FACS for expression of Gr1 and F4/80, which marked
the fractions of Gr1F4/80 granulocytes, Gr1F4/80 mono-
cytes, and Gr1 F4/80 double-positive or double-negative popula-
tions. In the presence of Sparc/ BM-MSCs, a significantly higher
fraction of Lin cells was driven toward granulopoiesis compared
with that of Lin cells cocultured with WT BM-MSCs or cultured
Figure 6. SPARC deficiency in the BM stroma associates with an enhanced myelopoietic response to TPO. (A) Histomorphologic analysis performed on hematoxylin
and eosin-stained BM sections from TPO-treated mouse chimeras shows that mice with Sparc/ stroma (WT  Sparc/, Sparc/  Sparc/) have significantly higher
numbers of immature granulocyte precursors (green arrows) and highly atypical/dysplastic MKs (red arrows) compared with chimeras having WT stroma (WT  WT,
Sparc/  WT). Four representative sections (1 per group) of the 20 evaluated are shown. Original magnifications 400. Scale bars represent 50 m. (B) Differential
hematopoietic cell counts (mean 
 SD) performed on BM sections of TPO-treated chimeric mice showing the different expansion of myeloid cell fractions of mice with a
Sparc/ or WT BM stroma. In each BM sample, the number of neutrophils, eosinophils, morphologically immature myeloid cells, erythroid cells, MKs, and lymphoid cells was
counted of 10 HPFs. *P  .05. **P  .01. Data are relative to counts performed on 2 different BM sections, per mice, per group. (C-D) Hematopoiesis in chimeric mice was
analyzed using a clonogenic colony culture assay. BM cells from chimeric mice were seeded in Methocult M3434 for 10 days, and the colonies that formed were scored and
photographed under an inverted microscope. (C) Representative images highlighting the enrichment of myeloid colonies in chimeric mice with Sparc/ stroma. (D) The
relative number of BM CFU-GM myeloid colonies (mean 
 SD) is significantly increased in Sparc/ recipient BM chimeras compared with WT recipient chimeras. *P  .05.
**P  .01. One representative experiment of the 3 performed with 5 mice per group is shown. (E) Hematopoietic progenitor cell numbers expressed as a percentage
(mean 
 SD) of total BM, showing the significant increase of GMP precursors in TPO-treated mice with Sparc/ stroma compared with the WT counterparts. *P  .05. The
data represent 1 experiment of the 3 performed with 5 mice per group. (F) Flow cytometric analysis of Gr1CD11b circulating myeloid cells performed on the PB mononuclear
cells of mouse chimeras. *P  .05. **P  .01. The data represent 1 experiment of the 3 performed with 5 mice per group. (G) Morphologic analysis of hematoxylin and
eosin-stained PB smears from BM chimeras show that circulating granulocytes from chimeric mice with Sparc/ recipient stroma are enriched in immature forms, including
pseudo-Pelger-Hu¨et and band-form nuclei, compared with circulating granulocytes from chimeras with WT stroma. Representative examples of circulating granulocytes from
2 smears per condition (of the 5 evaluated per experiment) are shown. Original magnifications 1000.
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alone (supplemental Figure 10B; P  .0284), indicating that the
absence of SPARC in BM mesenchymal cells results in the favored
expansion of specific myeloid cell populations.
Sparc deficiency in the BM microenvironment induces features
of a myeloproliferative disorder in the presence of Apcmin
mutant hematopoietic cells
The observation of an enhanced myelopoietic response to TPO in
the presence of a Sparc/ stroma prompted us to further investi-
gate the influence of stromal Sparc deficiency over myeloprolifera-
tion. To this aim, BM cells from 8-week-old Apcmin mutant mice
were transplantated into WT or Sparc/ recipients. Apcmin BM
cells were adopted because Apcmin mice display altered HSC
function and defective quiescence and develop an MDS/MPD
phenotype in the presence of HSC-extrinsic factors.38,39
Eight weeks after transplantation, chimeras were evaluated for
reconstitution and myelopoiesis. Apcmin  Sparc/ chimeras, but
not Apcmin  WT chimeras, displayed features of a myeloprolifera-
tive disorder, which included BM myeloid hyperplasia with
increased granulopoiesis and enrichment in morphologically imma-
ture myeloid cell clusters, as assessed by BM histopathology and
immunohistochemistry for Gr1 (Figure 7A) and by differential BM
hematopoietic cell count analysis (Figure 7B). FACS immunophe-
notypic characterization of BM precursors of Apcmin  Sparc/
chimeras revealed a significant increase of the Lin c-kit precur-
sors, and in particular of the GMP fraction compared with
Apcmin  WT chimeras (Figure 7C-D; P  .05). The hypergranu-
lopoiesis of Apcmin  Sparc/ mice was also highlighted by PB
FACS analysis, which revealed an expanded Gr1CD11b
circulating myeloid cell fraction (Figure 7E). The PB smears of
Apcmin  Sparc/ chimeras showed increase of circulating mature
granulocytes and immature or blast-like myeloid cells (Figure
7F-G). Excess myelopoiesis in Apcmin  Sparc/ chimeras was
also detected in the spleen by histopathologic analysis, which
revealed red pulp hyperplasia and partial effacement of the normal
splenic architecture (Figure 7H), and by FACS analysis showing
the increase of myeloid populations (supplemental Figure 11).
These results support the involvement of SPARC in the
crosstalk between hematopoietic cells and the stromal microenvi-
ronment and suggest the contribution of SPARC stromal deficiency
to the induction of local conditions favorable to myeloproliferation.
Discussion
Myeloproliferative conditions are paralleled by BM stroma remod-
eling events that variably involve modifications of the ECM,
ranging from the slight changes of nonfibrotic disorders to the deep
stromal disarrangement of osteosclerosis.6 Stromal modifications
may cast different influences on expanding myeloid populations
and residual hematopoietic components. In this context, the
functions of ECM proteins are poorly understood. In this study, we
described a role for SPARC, a nonstructural protein of the ECM, as
a stromal factor involved in the BM response to myeloproliferation.
We investigated SPARC expression in myeloid malignancies with
different degrees of associated stromal changes. SPARC was
confined to hematopoietic cells in cases devoid of stromal fibrotic
alterations, while being extensively expressed in stromal cells in
myelofibrotic cases. In the prototypical setting of PMF, increased
stromal SPARC expression correlated with the degree of stromal
modifications, with a higher prognostic risk score, and with
features reflective of impaired hematopoiesis, which implicated
stromal SPARC in the detrimental scenario caused by BM fibrosis
development and progression.
As a collagen chaperon involved in ECM assembly, SPARC has
been investigated in fibrotic conditions, including pulmonary,25
hepatic,40 and renal fibrosis,41 as well as cardiac infarction.42 In
these pathologic settings of inflammation-driven fibrosis, SPARC
is expressed by stromal cells and hematopoietic immune cells, and
its function is dependent on the cellular source. In bleomycin-
induced lung fibrosis, SPARC produced by stromal and inflamma-
tory cells promote collagen deposition and the resolution of
inflammation, respectively.25
In myelofibrotic myeloid malignancies, stromal remodeling is
not merely triggered by inflammation, although elevated pro-
inflammatory cytokine levels have been described,43 but rather it is
sustained by the self-activity of the myeloid clone. Neoplastic
myeloid cells synthesize a plethora of mediators, including TGF-
1, PDGFs, VEGFs, bFGF, and IGFs, which have been variably
implicated in the pathogenesis of myelofibrotic changes.6 It is
conceivable that these factors, sensed by BM mesenchymal cells,
could be responsible for the induction of SPARC stromal expres-
sion during myeloproliferation-related BM remodeling. Accord-
ingly, the analysis of genes whose expression is significantly
correlated with that of SPARC in BM hematopoietic and stromal
cells highlighted the remarkable correlation between SPARC and
some of the abovementioned axes (supplemental Table 2). These
included PDGFRA and TGFB1 (r2  0.96 and r2  0.96, respec-
tively; supplemental Figure 12A), both implicated in the pathogen-
esis of myelofibrotic myeloproliferative neoplasms.44,45 SPARC
may directly interact with PDGFs to regulate their binding to
cognate receptors.46 In addition, a reciprocal regulation between
SPARC and TGF-1 in stromal cells emerges from in vitro and
in vivo evidence,42,47 including our results showing TGF-1–
induced up-regulation of SPARC in murine BM-MSCs. Therefore,
SPARC expression in the BM stroma of myeloid neoplasms may be
induced by clone-derived mediators, such as PDGFs and TGF-1,
in an attempt to restore homeostasis in the BM milieu. The
persistence of myeloproliferation, which limits tissue normaliza-
tion, would eventually divert the effects of SPARC expression
toward detrimental fibrosis.
The role of SPARC in myelofibrosis development was investi-
gated using a model of TPO-induced myelofibrosis in WT,
Sparc/ mice, in which SPARC proved to be required for the BM
stromal remodeling triggered by reactive myeloproliferation. TPO
experiments on BM chimeras, in which hematopoietic cells were of
donor origin whereas stromal cells remained of host genotype,
identified BM stromal cells as the relevant source of SPARC for the
development of myeloproliferation-associated fibrosis. Moreover,
in vitro stimulation of murine BM-MSCs with TGF-1 showed
defective collagen fiber deposition in Sparc/ MSCs, which is a
probable mechanism for the reduced fibrosis of TPO-treated
chimeras retaining the host Sparc/ stroma.
SPARC inhibition by RNA interference has been reported to
effectively attenuate fibrosis in different cellular contexts, suggest-
ing a possible application of this approach to fibrotic diseases.40,48
A major caveat to the adoption of SPARC inhibition strategies in
myeloproliferation-related BM fibrosis may come from our results
showing that in the absence of stromal SPARC the myeloprolifera-
tive response to TPO was enhanced. Prompted by this observation,
we investigated whether the selective SPARC deficiency in the BM
stroma could favor myeloid cell expansion in the presence of a
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genetically determined HSC defect linked with altered myelopoi-
esis, such as the one characterizing Apcmin mice.38,39 In the Apcmin
model, the enhanced HSC function and the defective quiescence
resulting from increased Wnt--catenin signaling led to the
development of an MDS/MPD phenotype, which requires the
concurrence of HSC-intrinsic and microenvironmental factors.38
Figure 7. SPARC stromal deficiency induces features of a myeloproliferative disorder in the presence of Apcmin mutant hematopoietic cells. BM chimeras were
obtained by transplanting BM hematopoietic cells from Apcmin donors into either WT or Sparc/ recipients to obtain Apcmin  WT and Apcmin  Sparc/ BM chimeras
(n  5 mice per group, per experiment). The data shown represent 1 experiment of 2 performed. (A) Histomorphologic and immunohistochemical analysis performed on BM
sections from Apcmin  WT and Apcmin  Sparc/ BM chimeras highlights that the BM of Apcmin  Sparc/ (top right and middle right panels) chimeras is hypercellular
compared with that of Apcmin  WT chimeras (top left and middle left panels) because of the marked expansion of mature granulocytes (marked by Gr1 in bottom panels, DAB,
brown signal) and morphologically immature myeloid precursors. Four representative sections (1 hematoxylin and eosin-stained and 1 Gr1-immunostained, per group) of the
20 evaluated are shown. Original magnifications: top panels 200, middle panels 400, bottom panels 200. Scale bars: top panels 100 m, middle panels 50 m, bottom
panels 100 m. (B) Differential hematopoietic cell counts (mean 
 SD) performed on BM sections of Apcmin  WT and Apcmin  Sparc/ BM chimeras show the prominent
increase in the granulocyte myeloid cell fraction of Apcmin  Sparc/ mice. In each BM sample, the number of neutrophils, eosinophils, morphologically immature myeloid
cells, erythroid precursors, MKs, and lymphoid cells was counted of 10 HPFs. **P  .01. ***P  .001. ****P  .0001. Data are relative to counts performed on 2 different BM
sections, per mice, per group. (C-D) Fractions (C; percentage of total BM cells, mean 
 SD) and absolute numbers (D; mean 
 SD) of myeloid progenitor populations
[Linc-kit (LK), CMP, GMP, and MEP] showing the significant enrichment of GMP precursors in the BM of Apcmin  Sparc/ chimeras compared with Apcmin  WT chimeras.
*P  .05. (E) Flow cytometric analysis of Gr1CD11b circulating myeloid cells performed on the PB mononuclear cells of Apcmin  WT and Apcmin  Sparc/ chimeras
showing the significant expansion of circulating granulocytes characterizing Apcmin  Sparc/ mice. *P  .05. (F) Hematoxylin and eosin-stained PB smears preparations of
Apcmin  WT and Apcmin  Sparc/ highlighting the granulocytosis associated with BM stroma SPARC deficiency. Representative areas from 2 smears (of 5 evaluated) per
condition are shown. Original magnifications: top panels200, bottom panels400. Scale bars: top panels 100 m, bottom panels 50 m. (G) Morphologic analysis of hematoxylin and
eosin-stained PB smears from BM chimeras show that circulating granulocytes from Apcmin Sparc/ are enriched in immature and blastlike forms compared with circulating
granulocytes from chimeras with WT stroma. Representative examples of circulating granulocytes from 2 smears per condition (of the 5 evaluated per experiment) are shown.
Original magnifications 1000. (H) Histopathologic analysis of the spleen of Apcmin  WT and Apcmin  Sparc/ chimeras showing that the splenic parenchyma of
Apcmin  Sparc/ mice is characterized by the expansion of the red pulp (RP) resulting from increased extramedullary myelopoiesis, and by the effacement of the white pulp
(WP). Original magnifications: top panels 100, bottom panels 200. Scale bars: top panels 200 m, bottom panels 100 m.
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Therefore, the Apcmin represented a suitable experimental setting to
investigate the influence of a SPARC-deficient microenvironment
on MDS/MPD-prone HSC with preserved reliance on stromal
signals. Transplantation of Apcmin BM cells into Sparc/ recipients
resulted in a myeloproliferative disorder classified in mice as
“myeloproliferation-nonreactive,”49 which was different from the
MDS/MPD observed in Apcmin mice, underlining the driving contribu-
tion of the stromal environment to the outcome of the myeloprolif-
erative spur. The myeloproliferative phenotype of Apcmin  Sparc/
chimeras consisted of BM hypergranulopoiesis with increased
numbers of circulating mature granulocytes and myeloid precur-
sors and was not observed in Apcmin  WT chimeras, further
indicating that SPARC deficiency in the BM stroma may represent
a condition favoring myeloid expansion under a myeloproliferative
stress. Recently, Siva et al have reported that SPARC is dispensable
for murine hematopoiesis both at the steady state and under the
stress induced by acute hemolysis or BM transplantation,50 suggest-
ing that SPARC deficiency does not alter the hematopoietic
potential of the BM and that its contribution to the 5q MDS
phenotype may be subordinated to that of other molecular events
that are not recapitulated in Sparc/ models. We obtained similar
results in the BM transplantion setting, in which Sparc/ recipi-
ents were reconstituted without difference from WT recipients,
even in the presence of low numbers of donor Lin cells (ie,
2  103 cells, data not shown). This suggests that a true myelopro-
liferative spur complementing the total body irradiation is neces-
sary to bring out the role of SPARC in myeloproliferation. Indeed,
the enhanced myelopoietic response of mice with Sparc/ BM
stroma to TPO stimulation and to Apcmin hemopoietic cell transplan-
tation indicates that the downstream effects of stromal SPARC
synthesis, including collagen fibers assembly and deposition, may
affect the control exerted by the BM stroma/HSC interaction over
myelopoiesis.
The complex role of stromal SPARC in myeloproliferative
conditions emerging from our experimental results is coherent with
the homeostatic nature of matricellular proteins critically involved
in tissue repair and normalization.19 Some of these proteins, such
as thrombospondin-1 and osteopontin, whose role in the patho-
genesis of myelofibrotic myeloid neoplasms has been postu-
lated, share with SPARC detrimental effects on the BM stroma
homeostasis related to their up- or down-regulation in hemato-
logic malignancies.51-54
Merging together our results from in situ expression analyses on
human myeloid neoplasms and in vivo mouse models, we could
hypothesize that the BM stroma response to myeloproliferative
stimuli is entwined with the status of stromal SPARC expression.
Increased or defective expression of SPARC in the BM stroma may
exert different, yet detrimental, effects by fostering the develop-
ment of fibrotic changes or inducing a flawed stromal niche
permissive for the deregulated myeloid expansion, respectively. A
possible limit to the generalization of this latter event related with
defective stromal SPARC expression is represented by the evidence
that in our models of TPO-induced reactive myeloproliferation and
Apcmin  Sparc/ transplantation the role of the stromal microen-
vironment was pivotal to the determination of the myeloprolifera-
tive phenotype. Indeed, this frame might not fit models of
myeloproliferative disorders, such as those related with JAK2 or
MPL gain-of-function mutations, in which hematopoietic cell-
intrinsic defects are sufficient to determine the full-blown myelopro-
liferation in the absence of a recognized stromal contribution.55 In
this light, a role for BM stroma-derived SPARC may be envisaged
in the early stress response of the BM microenvironment to
myeloproliferation. Variations in SPARC stromal expression may
allegedly be accomplices in the loss of BM hematopoietic homeo-
stasis associated with stroma disarrangement and/or altered
myelopoiesis.
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